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In many circumstances, individuals do not respond identically to the same treatment.
This phenomenon, which is called treatment response heterogeneity (TRH), appears to be
present in treatments for many conditions, including obesity. Estimating the total amount
of TRH, predicting an individual’s response, and identifying the mediators of TRH are of
interest to biomedical researchers. Clinical investigators and physicians commonly postu-
late that some of these mediators could be genetic. Current designs can estimate TRH as
a function of specific, measurable observed factors; however, they cannot estimate the
total amount of TRH, nor provide reliable estimates of individual persons’ responses. We
propose a new repeated randomizations design (RRD), which can be conceived as a gen-
eralization of the Balaam design, that would allow estimates of that variability and facilitate
estimation of the total amount of TRH, prediction of an individual’s response, and identifi-
cation of the mediators of TRH. In a pilot study, we asked 118 subjects entering a weight
loss trial for their opinion of the RRD, and they stated a preference for the RRD over the
conventional two-arm parallel groups design. Research is needed as to how the RRD will
work in practice and its relative statistical properties, and we invite dialog about it.
Keywords: treatment response heterogeneity, crossover design, Balaam design
INTRODUCTION
Due to the varied environmental, genetic, and physiological milieu
from person to person, a given treatment does not produce the
same response in all patients. Weight loss treatments for obe-
sity and its related comorbidities are no exception, and a wide
range of weight loss and metabolic changes occurs with most
treatments (Bouchard et al., 1990, 1994; Bray, 2008; Puzziferri
et al., 2008). While variability in response to a given treatment
occurs among persons in many clinical conditions, we shall use
obesity as an example to illustrate the effects of this phenom-
enon for purposes of exposition. Obesity, like many chronic
conditions the medical community faces, is a complex condi-
tion likely to have many causes and many solutions (McAllister
et al., 2009). Certain genes are established contributors to phe-
notypic variation in body mass index (BMI; Wang et al., 2012),
and it is possible that genotypic variation could also contribute
to variation in response to a weight loss treatment. Quantify-
ing variation in treatment response and identifying “responders”
and “non-responders” would improve treatment allocation for
any complex disease, and is imperative for optimizing obesity
treatment for individuals in a heterogeneous population. In addi-
tion, quantifying variation due to patient-treatment interaction
is of interest to all investigators seeking to identify effective obe-
sity treatments, as it is a source of variation that, if identified,
could lead to a clearer picture of a treatment’s effect among
persons.
Several approaches are currently used to examine heterogene-
ity in treatment response. Association between degree of change in
the outcome variable from baseline with other baseline covariates
is often used to identify predictors of change in the outcome vari-
able (Sysko et al., 2010; Guaraldi et al., 2011). In addition, genome
wide association studies (GWAS) are used to estimate the amount
of inter-individual variability in weight loss that is due to genetic
differences (Sarzynski et al., 2011), and behavioral compensation
(e.g., increased energy intake or decreased non-exercise energy
expenditure) has been proposed as an explanation for among
person variability in weight loss when subjects lose less weight
than predicted (Manthou et al., 2010; Turner et al., 2010). Covari-
ates such as genotype, age, starting weight, race, or gender can
explain a portion of the inter-individual variability in weight loss
trials, but we are left knowing neither the magnitude of the total
inter-individual variability nor the proportion of inter-individual
variability that those covariates explain.
There is a gap, however, between standard methods for assessing
a treatment’s efficacy and our desire to characterize this inter-
individual variability in treatment response, which is called treat-
ment response heterogeneity (TRH). Methods currently employed
do not allow for quantification of individual treatment response,
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which is defined as the difference between the change in the out-
come variable following treatment compared to change in the same
outcome variable if the same individual had received the control
treatment in the same period of time (Gadbury, 2010). A com-
mon mistake made when discussing treatment effect is labeling
an observed change as a response. For instance, let us consider
Figure 1, which is an illustration of potential situations that could
occur in a two-arm parallel groups randomized controlled trial
(RCT).D refers to the difference between weight loss on treatment
and weight loss on control, or D=T −C, µD is the population
mean of D, and TRH refers to the variance in D that is due to
subject-treatment interactions. Subjects A and G in Figure 1A
would often be labeled “non-responders” if a standard two groups
design were used in the RCT. As is revealed in Figure 1B, however,
both subjects would have gained 0.5 kg on the control, making
the treatment effect for subjects A and G 0.5 kg lost, just like
all of the other subjects. Even though no change is observed for
subjects A and G in the treatment group, the effect of the treat-
ment on these subjects is not necessarily zero. Therefore, the label
“non-responder” is unjustified if derived in a standard design.
Figures 1C,D both show a mean weight loss of 1.57 kg, indicating
an average treatment effect of 0 kg lost. However, the treatment
effect was non-zero for subjects A, C, E, and F.
Figure 1 illustrates several points concerning TRH: (1) It is
possible that µD 6= 0, but TRH= 0 (Figures 1A,B); (2) it is pos-
sible that µD= 0, but TRH> 0 (Figures 1C,D); (3) variability in
weight loss among subjects in the treatment group does not, by
itself, indicate the existence of TRH; and (4) subjects who lose the
least amount of weight do not necessarily have a weaker response
to the treatment. Observing individual changes provides an esti-
mate for mean population response, but no statements can be
made about individual responses in a conventional design.
Of the RCT designs that might be considered when discussing
estimation of variance due to subject-treatment interactions, the
two most well known are the two-period crossover design and
the Balaam design. In the two-period crossover design, subjects
are randomly assigned to one of two possible sequences of treat-
ment A and treatment B (or placebo): AB or BA. The two-period
crossover design cannot separate the inter-individual variability
in treatment response from other sources of variability (Senn,
2001). Tucker-Drob (2011) suggested adding a third sequence,
AA, to further distinguish between treatment effects and other
sources of variability. However, this approach does not allocate
multiple periods of each treatment to each individual, and thus it
has limitations for estimating subject-treatment interaction (Senn,
2001).
The Balaam design modifies the two-period crossover by
increasing the possible number of sequences that patients can be
randomized to: AA, AB, BA, or BB (Balaam, 1968). An advantage
of the Balaam design is that the effect of time-treatment inter-
actions can be accounted for. However, because participants in
a Balaam design do not experience multiple periods of all treat-
ments, estimates of TRH do not separate the variability due to
individual patient-treatment interaction from other sources of
variability (much like the two-period crossover design and the
design proposed by Tucker-Drob, 2011) (Senn, 2001). Addition-
ally, we can see that because only half the subjects receive both
treatments (in a balanced design), one could provide reasonable
estimates for the individual mean effect of treatment, as well as
the sample variance of those means, for only half of the patients
in the study sample (Balaam, 1968). The Balaam design enhances
the picture of how variable treatment effects are in a population,
but it does not uniquely estimate patient-treatment interactions
or the variance thereof.
FIGURE 1 | Hypothetical distributions of individual weight changes in a clinical trial. (A,B) Show µD 6=0, TRH=0, and (C,D) show µD =0, TRH>0.
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To bridge the gap between our current methods of assessing
treatment effects and the desired knowledge of inter-individual
variability in treatment response, we propose a novel RCT design
involving repeated randomizations of each subject to treatment or
control, which we refer to as the repeated randomizations design
(RRD). Figure 2 provides a diagram that compares the two-arm
parallel groups design (PGD), the two-period crossover design,
and the RRD. The Balaam design can be thought of as a special
case of the RRD with only two treatment periods. Alternatively, the
RRD can be thought of as a randomized form of aggregated n-of-1
trials, the non-randomized form having been discussed elsewhere
(Franklin et al., 1996; Zucker et al., 1997; Nikles et al., 2011).
Because of the nature of the randomization, which repeatedly
switches subjects between two treatments (or between a treat-
ment and a placebo), there are important practical restrictions
that dictate which interventions/conditions are appropriate for the
RRD. Two main characteristics influence whether an RRD design
is appropriate: (1) an individual can be easily switched from one
experimental intervention to the other; and (2) an individual can
be ethically switched from one experimental intervention to the
other. Minimal carry-over effects of the treatment, as well as the
ability to blind the treatment, are characteristics that are facilitative
but not critical. Clinical interventions for weight loss that would
often fit with these characteristics include, but are not limited
to: pharmaceuticals, dietary supplements and other dietary inter-
ventions, and exercise interventions. In contrast, gastric bypass
surgery would generally not be appropriate to test using the RRD.
The experimental intervention being tested is not restricted to
clinical interventions, but could test an aspect of metabolism,
behavior, or weight change that is of scientific interest, and sat-
isfies the characteristics laid out above (e.g., short-term metabolic
effects of different macronutrients).
The conduct of a trial using an RRD would proceed as follows.
N subjects would be randomized at baseline to either treatment
or control. After a pre-specified follow-up period, the outcome of
interest (e.g., weight change) would be measured on all subjects.
Subjects would then be randomized again to either treatment or
control. This process would continue for a total of p treatment
periods. With a large enough p, the probability of one subject
receiving only treatment (or only control) throughout the trial is
effectively zero. Specifically, the probability of receiving only treat-
ment or only control is ( 12 )
p+( 12 )p = 2( 12 )p = ( 12 )p−1. Therefore,
the authors suspect that participants would prefer such a design
compared to the classic PGD, in which an individual subject has
a 50% chance of receiving only control (in a balanced design).
With pT number of observations on treatment and pC number
of observations on control, the following estimates could be com-
puted, among others: (1) the sample estimate of the mean effect
of the treatment for an individual; (2) the sample estimate of the
variance of all individual mean effects of the treatment; and (3)
the sample estimate of the mean effect of the treatment for the
population. Estimation of the total amount of TRH would also
facilitate estimates of the proportion of inter-individual variabil-
ity in treatment response a covariate of interest might explain (e.g.,
genotype).
These multiple observations on each treatment for each subject
allow for more direct evaluation of individual subject-treatment
interactions (Senn, 2001). From this study design, investigators
will have not only an estimate for the mean effect of a treat-
ment within a population, but also, with making some relatively
mild and plausible assumptions (e.g., the non-estimable corre-
lation between the two treatment outcome variables is the same
across periods): (1) an estimate of the total inter-individual vari-
ability in treatment response; (2) the proportion of true non-
responders; and (3) the proportion of the population for whom
a standard treatment works better than an experimental treat-
ment, even though the experimental treatment appears to be
better on average. This design would thereby provide informa-
tion about individual responses, not just the population’s mean
response.
Because repeated randomization to different treatment groups
would greatly alter the study experience for participants, however,
FIGURE 2 | Comparison of a two-arm parallel groups design
(A), a two-period crossover design (B), and the RRD (C).
T represents the treatment group and C the control group; N is the
total sample size for each experiment; n is the group size for a
particular treatment condition at a particular time point (with
subscripts differentiating between unique groups of subjects); and p
is the treatment period (with subscripts identifying which treatment
period).
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we conducted a survey to determine how willing participants
would be to enroll in such a study.
MATERIALS AND METHODS
We ascertained how acceptable participating in such a design
would be by conducting a survey of subjects being screened for, or
already enrolled in, a weight loss trial investigating a diet interven-
tion (the Medifast 5 & 1 Plan). After obtaining approval from the
Institutional Review Board of the University of Alabama at Birm-
ingham, the protocol for the trial was modified to include a printed
questionnaire (The Clinical Trials.gov identifier NCT01211301).
Written informed consent was obtained from all subjects. Since
the survey was added after recruitment began, it was administered
to subjects at one of two time points: screening or follow-up. Some
subjects screened for the trial never took the survey because they
had already been screened out, or they were lost to follow-up after
randomization.
Subjects (n= 119) were given a description of two potential
trial designs (see Table 1), and 118 completed the survey. Trial A
described the standard PGD (similar to that used in the trial for
which they were being screened), and trial B described the RRD.
The five-question instrument investigated which design subjects
preferred, in which design subjects believed they were more likely
to enroll, and which design they believed they would be more likely
to complete. The scales for questions 2 through 5 were 1–5. When
the survey was administered to participants, the scale for ques-
tions 2 and 3 used 1 as the most negative response and 5 as the
most positive response. Questions 4 and 5 were reverse scored so
that 1 was the most positive response and 5 was the most negative
response. This reversal was done to decrease the effect of acquies-
cence (Cloud and Vaughan, 1970). In the analyses, the responses
to question 4 were flipped to the other side of the scale (e.g., a
response of “4” became a response of “2”). The same process was
done for the responses to question 5.
Summary statistics were estimated for all five questions and the
available demographic variables. Two null hypotheses were tested.
The first null hypothesis was that participants believed they were
equally likely to enroll in a trial using the PGD as a trial using the
RRD. The second null hypothesis was that participants believed
they were equally likely to complete a 2-year trial using the PGD
as a 2-year trial using the RRD. To test these two null hypotheses,
we used paired Wilcoxon signed rank tests with α= 0.05. Paired
tests were used because all participants answered all questions, so
a comparison of responses to questions two and three (hypothesis
one) and questions four and five (hypothesis two) involved paired
data. Non-parametric rank based methods were used as a natural
choice for ordinal scale data such as these (Gardner and Martin,
2007).
RESULTS
Age in the study sample ranged from 20 to 63 years, with a
mean (SD) of 40.9 (9.7) years. The ethnic groups represented
were White (24.7%),Black/non-Hispanic (73.3%),Black/Hispanic
(0.9%), and Asian (0.9%). Females comprised 87.2% of the study
sample.
Descriptive statistics of the responses are provided in Table 2.
When given a choice between the PGD and the RRD (question 1),
63.6% (95% CI: 54.9, 72.2) preferred the RRD. A paired Wilcoxon
signed rank test comparing question 2 and question 3 revealed
that subjects believed they were significantly more likely to enroll
in a trial using the RRD (S=−269.5, p= 0.04). However, there
was no significant difference in subjects’ stated beliefs about how
likely there were to complete a 2-year trial using one design instead
of the other (S=−77, p= 0.31).
DISCUSSION
We have reported results of a questionnaire from a pilot study
that indicates future participants in weight loss trials might pre-
fer to participate in a trial using an RRD to a trial using a PGD.
This finding gives some indication that further development of
the RRD could be worthwhile. Because the questionnaire was a
pilot study, the questionnaire did not undergo rigorous psycho-
metric evaluation. However, we believe that the descriptions of
the two trials were clear, and that the questions themselves were
understandable to the average participant in a weight loss trial.
Additionally, participants in our study were enrolled in a clinical
trial testing a dietary intervention, not a pharmaceutical interven-
tion, and it is unknown whether participant opinions of the RRD
in a trial testing a pharmaceutical would be different.
As stated previously, the RRD would be inappropriate for
evaluating some types of treatments, including pharmaceuticals,
as well as for some types of conditions. Pharmaceuticals, for
example, that have considerable carry-over effects might not be
well-suited for study with the RRD. Additionally, if the condition
Table 1 | Description of designs given to study participants.
Design Description
Study A – single ran-
domization design
In study A, the classic design, if you were to participate you would be randomly assigned to take either the active drug being
studied or to a pill with no drug (a placebo). There would be a 50% chance that you will be assigned to take the placebo. The
study would be run “double blind” so that neither you nor the study staff would know whether you are taking the active drug or
the placebo until after the study is over. The study will proceed like this for 24 months (2 years), and every month you would be
asked to come to the clinic and be weighed.
Study B – repeated ran-
domization design
In study B, a new design, if you were to participate, you would be randomly assigned each month to the active drug being studied
or to a placebo. You would be assigned to the active drug or placebo an equal number of times; that is, you would be guaranteed
to get the drug for 12 of the 24 months in random order. The study will be run “double blind” so that neither you nor the study
staff will know whether you are taking the active drug or the placebo during any particular month.The study will proceed like this
for 24 months (2 years), and every month you would be asked to come to the clinic and be weighed.
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under study were immediately dangerous or life-threatening, then
rapidly switching a participant on and off treatment might not be
ethical.
Clinical interventions are believed to produce varied results
among persons (e.g., a treatment may produce a different magni-
tude or direction of response in individuals with different geno-
types), but current RCT designs cannot estimate the extent of
this inter-individual variability in response. We have proposed an
alternative design, which would allow for estimation of the total
inter-individual variability in treatment response. Furthermore,
evidence from a pilot survey suggests subjects might prefer the
RRD to the conventional PGD. We conclude with several topics
for future research related to optimizing the use of the RRD:
1. What are the most appropriate analytical procedures for esti-
mating the quantities of interest (i.e., the proportion of the
population with negative responses, the proportion of true
non-responders, and the proportion of the population that
genuinely responds better to a treatment that is inferior to an
alternative treatment, on average)?
Linear mixed models would likely be an appropriate method
to use, since they allow for modeling at the individual level
(Mallinckrodt et al., 2003). Additional topics concerning the
analysis procedure, such as the handling of missing data, could
be addressed using established methods (e.g., multiple impu-
tation; Elobeid et al., 2009). Research comparing such analytic
approaches in RRDs would be warranted.
2. What is the relative efficiency of the RRD compared with the
PGD for estimating interactions between treatment effects and
measured covariates (e.g., genotype)? What is the relative effi-
ciency of the RRD compared with the PGD for estimating mean
treatment effects?
The relative efficiency will likely depend upon the degree of
residual dependence across time, within individuals, as well as
other factors. Deriving analytic expressions of the relative effi-
ciency under varying circumstances would help investigators
to choose between RRDs and PGDs when such questions are
of interest.
3. What are the advantages and disadvantages of constraining the
randomizations so that each subject receives an equal allocation
of treatment and control periods?
At a social level, there are marked advantages to such constrain-
ing because completely randomized allocation of treatment
periods in a long-term trial, in which a placebo is the compar-
ison treatment, can make some subjects hesitant to participate
(AD2000 Collaborative Group, 2004). Each subject will then
know that they will receive active treatment at least half of the
time. Additionally, equal sample sizes within an individual (i.e.,
equal number of treatment and control periods) would allow
for greater precision in estimating an effect of treatment for
a given individual. A disadvantage is that if the study is not
completely blinded, at some point a patient’s next treatment
condition will be predictable.
4. How would the RRD actually affect subject recruitment and
retention?
Our study reported how likely one group of subjects believed
they would be to complete a trial using the RRD. It is well
known that drop-out rates in obesity trials can be quite large
(Elobeid et al., 2009). The actual effect of the RRD on subject
retention cannot be known until a RRD is used.
APPLICATION TO PHARMACOGENETICS
Since the RRD could estimate the total inter-individual variabil-
ity in treatment response, it could help determine the poten-
tial impact of subsequent analyses attempting to explain that
variability. Standard methods of estimating the proportion of
variability in a phenotype attributable to genetics exist (e.g.,
GWAS). These methods can be expensive. Therefore, knowing
when the probability for a “return on the investment” is small
(i.e., when the total TRH is small) might be helpful to both inves-
tigators and funding bodies. To our knowledge, no other RCT
designs can provide estimates of total TRH as reliable as the
RRD.
We hope this work will spark dialog within the scientific com-
munity regarding estimation of inter-individual variability in
treatment response, as well as the feasibility of the RRD.
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Table 2 | Survey questions, potential responses, and summary statistics of responses.
Question Potential responses* Mean (95% CI) Median Range
(min, max)
2. If only design A were available to you, how likely would you be to enroll? 1 2 3 4 5 3.9 (3.7, 4.1) 4 4 (1, 5)
3. If only design B were available to you, how likely would you be to enroll? 1 2 3 4 5 4.1 (3.9, 4.3) 4 4 (1, 5)
4. If you enrolled in a trial of design A, and it was a 2 year trial, how likely
would you be to complete the trial?
1 2 3 4 5 3.9 (3.7, 4.1) 4 4 (1, 5)
5. If you enrolled in a trial of design B, and it was a 2 year trial, how likely
would you be to complete the trial?
1 2 3 4 5 4.0 (3.8, 4.2) 4 4 (1, 5)
*1 is the most negative response, and 5 is the most positive response. 3 is a neutral response.
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